Quick Grounding: Who are we talking to?

• Which of these best describes your role in this investment? Options: PE Operating Partner / Value Creation Lead, Portfolio Company CEO / President, CFO / Finance Lead, Fund Principal / GP, Portfolio Operations Director, Board Member / Chair, Other
• Which portfolio company (or platform) is this engagement focused on?
• What was the immediate trigger for initiating this alignment conversation? Options: Missed EBITDA target >10%, Mid-hold review behind model by months, New platform acquisition—set trajectory from day one, Pre-earnout / exit preparation, Other (please specify)
• How urgent is the need to act (from the perspective of the IC and sponsor leadership)? Options: Immediate (30 days), Near-term (60–90 days), Quarterly (3–6 months), Flexible (6–12 months)
• Who else from your firm or the portfolio company will be critical to this discovery (names/roles)?

Starting Point: Who's Really in Charge?

• If we had to name the single person who can green-light the operational changes needed to deliver 3–5 points of EBITDA, who is it—and why isn’t that obvious?
• Which parties currently hold formal decision rights for strategic/operational changes? Options: Investment Committee, Sponsor GP, Portfolio Company Board, CEO / Management Team, Majority Lender / Bank, Minority Investor with consent rights, Other
• Are any decision rights conditional (e.g., thresholds that trigger IC approval vs. board sign-off)? Please describe.
• How quickly can the primary decision-maker(s) be convened to approve a recommended intervention? Options: Within 24–72 hours, Within 1–2 weeks, Within 2–4 weeks, Longer than a month
• Can you share an example where unclear decision rights materially slowed or derailed an operational change?

What's the Real Timeline (not the optimistic one)?

• Which timeline would your IC dismiss as unrealistic—and what timeline would they privately expect to protect the deal thesis?
• What specific deadline(s) or events create hard windows for results (e.g., covenant test dates, IC reviews, refinancing milestones)?
• What is the IC’s target window for realizing the EBITDA improvement (primary preference)? Options: 0–3 months, 3–6 months, 6–12 months, 12–18 months, Longer / multi-year
• If diagnostic work shows capital is required to unlock savings, how flexible is the timeline for approving that capital? Options: Highly flexible, Somewhat flexible with IC approval, Only flexible with lender consent, Not flexible—no additional capital available
• Concretely, what happens if targets are missed by one quarter? (Select all that apply.) Options: Request for covenant waiver, IC escalation / remediation plan, Management change considered, Refinancing discussion, No immediate consequence, Other

What Would Success Look Like to Your Investment Committee?

• If your IC could write a one-sentence mandate for this engagement—what would it demand and what would it forbid?
• Which primary success metrics will the IC use to judge this engagement? Options: Realized EBITDA (absolute), EBITDA margin points, Free cash flow / cash conversion, Cost savings by category (COGS/SG&A), Revenue uplift, Covenant headroom / leverage reduction, Multiple / exit readiness
• What secondary metrics, if they deteriorate, could still cause the IC to view the engagement as not successful (e.g., customer churn, NPS, employee turnover)? Options: Customer churn, NPS / customer satisfaction, Employee churn / key talent loss, Quality metrics / returns, Service levels, Other
• What reporting cadence and format will satisfy the IC for both diagnostic and execution phases? Options: Weekly dashboard + exceptions, Bi-weekly steering review, Monthly IC packet, Quarterly deep-dive, Ad-hoc as required
• How granular will the IC expect validation of savings (e.g., line-item P&L, vendor confirmations, customer proofs)? Options: Top-line estimates acceptable, P&L line-item detail, Third-party validation / vendor proofs, Customer contract evidence, Combination—depends on size

The Buy-In Map — Who Needs to Be Moved?

• Which individual stakeholder, if unconvinced, can quietly derail the plan even if everyone else agrees?
• Which internal stakeholders do we need to secure explicit buy-in from before embedding teams? Options: CEO, CFO, COO / Ops Head, Head of Sales, Head of Procurement, HR / Head of Talent, Board Chair, Other
• How would you characterize management’s current openness to external interim operators leading day-to-day change? Options: Welcoming and collaborative, Cautiously open, Ambivalent / mixed, Resistant
• Which levers have historically moved resistant stakeholders (pick all that apply)? Options: Aligned compensation / success fees, Stepped governance with IC sponsorship, Short pilot / low-disruption proof, Dedicated knowledge-transfer plan, Assurances on headcount decisions, Other
• For the stakeholders likely to resist, what are their core fears or objections (be specific)?

Deal Risks That Eat the Best Plans

• What single constraint today would make our recommended operational plan impossible to deliver?
• Which risk categories are present and material right now? Options: Debt covenants / leverage tightness, Insufficient available capital, Supplier contractual limits, Labor / union constraints, IT / data gaps, Customer concentration, Regulatory / compliance limits, Market decline
• Are any covenants currently close to being triggered? If so, which and by how much?
• Estimate the likely incremental capital required to unlock top operational opportunities. Options: No material capital, Under $1M, $1M–$5M, $5M–$20M, Over $20M, Unknown / need analysis
• How quickly could additional capital be approved or sourced if diagnostics recommend it? Options: Within 1–2 weeks, 1–2 months, 3–6 months, Not feasible during hold period

Governance & Escalation — How Will Decisions Stick?

• If an initiative hits a roadblock on day 45, who is authorized to override the obstacle—and what would that override look like?
• What governance cadence do you want for the 100-day diagnostic and the first 12 months of execution? Options: Weekly ops reviews, Bi-weekly steering committee, Monthly IC updates, Quarterly executive reviews, Ad-hoc escalation only
• Who should sit on the steering committee to ensure both speed and accountability? Options: Sponsor Operating Partner, CEO, CFO, COO, Head of HR, Board Representative, External Value Creation Lead
• Describe your desired escalation path from working team → steering committee → IC. What timeframes and approvals should be required?
• Would success-linked commercial terms (e.g., portion of fees paid on realized savings) make it easier to secure stronger governance and faster decisions? Options: Yes, Maybe, No
• What decision gates do you want defined for major initiatives (examples: go/no-go at 30/60/90 days)? Options: 30/60/90 gates, Milestone-based gates tied to savings, IC sign-off only for capital requests, Other / custom

Closing the Loop — Alignment, Commitments, and Next Steps

• Imagine a month from now every stakeholder says they are aligned—what single tangible artifact or approval would prove true alignment?
• What immediate next step would you want us to take after this discovery? Options: Prepare a one-page alignment memo, Run a focused 2–3 week diagnostic pilot, Schedule steering committee meeting, Draft proposed commercial terms (incl. success fee), Other
• Who must sign off to proceed to a 100-day diagnostic (roles/names)?
• What information and system access must be available before embedding teams? Options: Historical P&L and forecasts, ERP / GL access, Contracts (customers & suppliers), Procurement spend data, Operational KPIs and dashboards, HR org chart and payroll data
• By what date can those materials/access realistically be provided? Options: Within 1 week, Within 2–4 weeks, Within 1–2 months, Uncertain / needs coordination
• What cultural or human-capital risks should we prepare for when embedding (e.g., fear of layoffs, leadership fatigue, union sensitivity)?

Setting the Scene: Who Are We Helping Today?

• Tell us the company name, primary business lines, and the fund/operating partner sponsoring this engagement.
• What triggered bringing an external value-creation partner into this situation? Options: Missed EBITDA target (>10%), Mid-hold review shows synergy lag, New platform acquisition (day‑one alignment), Pre-exit acceleration, Other
• Who will be the ultimate decision-owner for approving diagnostics and funded initiatives? Options: PE operating partner, Portfolio company CEO, Investment committee, CFO/Finance committee, Board representative, Other
• How urgent is the need to close the EBITDA gap (choose the best fit)? Options: Immediate (days–weeks), Short (1–3 months), Moderate (3–6 months), Longer-term (>6 months)
• Describe briefly what 'successful' looks like from the sponsor’s perspective over the next 12 months.

If the Deal Model Was a Map, Where Did the Compass Break?

• Which explicit deal assumptions look most at risk today—volume, price, synergies, cost base, working capital, or something else? Options: Volume/volume mix, Realized pricing, Procurement/supplier savings, Manufacturing/COGS, SG&A run-rate, Working capital, Other
• By how much (absolute or percentage) are actual metrics deviating from the model on the top 3 drivers?
• Which assumption gap surprised you the most and why?
• Have sensitivities or downside scenarios been run against the covenant and liquidity plan since performance drift began? Options: Yes—recent stress test, Yes—but outdated, No, not yet, Unsure
• If you had to pick the single biggest erroneous assumption that, if corrected, would materially improve confidence in the model, what would it be?

Where the Numbers Hide the Pain: Financial Reality Check

• Which financial metrics have deteriorated most sharply in the last 6–12 months? Options: EBITDA margin, Gross margin, Working capital days, Cash conversion cycle, EBITDA run-rate, Other
• Are there material one-off charges, accounting timing issues, or carve-outs currently masking true run-rate profitability? Options: Yes—one-offs explain most gap, Partially—some timing noise, No—gap is structural
• How reliable and auditable is the current P&L by product, channel, or plant when we need to model opportunity by line item? Options: Highly reliable, Mostly reliable with pockets of noise, Significant gaps/needs reconciliation, We don't currently have that granularity
• Which cost categories have been the focus so far (if any)? Options: Purchasing/procurement, Manufacturing labor/efficiency, Freight/logistics, SG&A headcount, Contractor/consulting spend, Other
• Please provide the trailing twelve months (TTM) or last fiscal year EBITDA, revenue, and working capital days (free response — paste numbers or attach key note).

What's Really Getting in the Way on the Floor and in the Field?

• If you listen to front-line managers, what single operational complaint do they raise most often? Options: Capacity constraints, Poor quality/rework, Supplier lead times, Inventory stockouts/overstock, System/data latency, Other
• Where are the recurring bottlenecks—specific plants, SKUs, routes, or teams—that materially impact margin or service?
• How much working capital is tied up in obsolete or slow-moving inventory versus seasonally appropriate buffers? Options: Mostly obsolete/slow moving, Balanced, Mostly seasonal/intentional, Unknown
• On procurement: do you have centralized contracts and leverage, or is buying decentralized by site/business? Options: Centralized with master agreements, Hybrid—category centralization, Fully decentralized, In process of centralizing
• What manufacturing or service KPIs are tracked daily and where do they consistently miss target?

Decision Friction: Who Can Actually Pull the Trigger?

• When proposed initiatives require tradeoffs (e.g., short-term margin vs. working capital), who has final say and how quickly are such decisions made? Options: CEO/MD, CFO, Operating partner + CEO consensus, Board/investment committee, Escalation required—time varies
• Describe recent examples where an operational recommendation was stopped, delayed, or diluted—what happened and why?
• How aligned is the management team to taking externally led, interim-operator style interventions? Options: Welcoming/partnering, Cautiously open, Resistant but negotiable, Actively resistant
• What formal governance cadence exists today (meeting frequency, KPIs reviewed, escalation path)? Options: Weekly ops reviews, Biweekly/monthly, Quarterly only, Ad hoc/no formal cadence
• What incentives or accountability mechanisms (bonus, scorecards, promotion paths) would support rapid initiative adoption?

Risk Radar: What Could Derail Improvements Overnight?

• Which of these risk categories is most likely to block execution in the near term? Options: Debt covenants/liquidity, Required capex vs. covenant limits, Customer contract erosion, Supplier failure or single-source risk, Regulatory/compliance issues, Labor relations/union risk
• Are there upcoming covenant tests, refinancing events, or cash shortfalls in the next 6–12 months we should prioritize modeling? Options: Yes—specific dates known, Yes—approximate timing, No imminent tests, Unsure
• Do any identified EBITDA opportunities require capital investment that conflicts with current debt covenants or liquidity plans? Options: Yes—material capex required, Some initiatives need modest capex, No—primarily cash-neutral initiatives, Unknown
• Which customers or suppliers represent concentrated commercial or supply risk (top 5 by revenue/procurement)?
• If a worst-case scenario unfolded (market drop, supplier failure, covenant breach), what immediate operational priorities would you pursue?

Past Remedies: Why Prior Fixes Didn’t Stick

• Tell the story of the last material improvement program—what was attempted and what ultimately prevented sustainable results?
• Were owners and specific, measurable acceptance criteria assigned to those initiatives? Options: Clear owners + measurable criteria, Owners but weak metrics, No clear ownership, Partial/uncertain
• How often did governance review progress and what corrective actions were taken when milestones were missed? Options: Weekly with escalation, Monthly with adjustments, Quarterly/no rapid correction, Ad hoc
• What people or cultural dynamics (e.g., fear of change, turf protection) most often undermined execution?
• If you could redesign one element of how improvement programs are run here, what would you change first?

Can We Trust the Data? The Instruments and Dashboards

• Which core systems house transactional and master data (ERP, WMS, CRM, BI)? Please list systems and primary owner.
• How quickly can we get clean P&L by product/plant/month and transactional PO/invoice history for the last 12 months? Options: Within 1 week, 1–3 weeks, 1+ month, Not currently available
• Which KPIs are used daily to run the business and which are used only for monthly/board reporting?
• Are there known data integrity issues (duplicate SKUs, mismatched units, delayed feeds) that will require reconciliation work? Options: Significant issues, Some housekeeping required, Minor/no issues, Unknown
• Who on the finance/ops team will act as the primary data liaison for a 100‑day diagnostic?

If We Could Snip One Constraint Now, What Would Unlock the Most Value?

• Imagine we could change one thing this quarter that materially improves EBITDA—what would you choose and why?
• Which interventions are politically acceptable today (pricing changes, headcount adjustments, supplier renegotiations, temporary operational overrides)? Options: Pricing & commercial changes, Headcount/SG&A adjustments, Supplier renegotiation, Manufacturing overtime/resequencing, Working capital levers, None are acceptable
• What timeline do you consider realistic to see the first meaningful EBITDA improvement (pick best fit)? Options: <30 days, 30–90 days, 90–180 days, >180 days
• What minimum EBITDA uplift (in margin points) would you need within 12 months to regain confidence in meeting the investment thesis? Options: <1 point, 1–2 points, 3–4 points, 5+ points, Unsure
• What trade-offs would you accept to achieve that uplift (temporary service impact, one-time severance, CAPEX deferral, pricing increases)?

Making the Ask: Practical Readiness and Next Steps

• If we were to run a focused 100‑day diagnostic, what practical barriers must be removed first (data access, exec time, NDA, site access)? Options: Immediate data access, Executive time commitment, Site visits allowed, NDA/commercial terms, Other
• Who needs to be briefed and aligned before a diagnostic kickoff (names/roles)?
• What would make you want to say yes to an engagement proposal quickly—speed, price, risk-share, references, pilot scope? Options: Speed to start, Fee structure (success fee), Risk-share model, Sector references/case studies, Pilot diagnostic on a single site
• Are there any confidentiality, compliance, or stakeholder considerations (LPs, co-investors, unions) we must navigate up-front? Options: Yes—regulatory/LP restrictions, Yes—labor/union constraints, No major constraints, Unknown
• Finally, what would be the single most persuasive outcome from a 100‑day diagnostic that convinces the investment committee to proceed to execution?

Opening: Quick Reality Check

• What's the immediate trigger that brought you to consider external value-creation support right now? Options: Missed post-acquisition EBITDA target (>10%), Synergy capture lagging deal model (≈6+ months), New platform acquisition—set direction from day one, Mid-hold performance review flagged risk, Other
• What is the fund's target hold period for this asset and how urgent does the committee consider intervention? Options: <12 months (very urgent), 12–24 months (urgent), 24–36 months (moderate), >36 months (longer runway)
• Who is the single person ultimately accountable to the investment committee for operational delivery on this engagement?
• Briefly, what have you already tried internally or with outside advisors to close the EBITDA gap—and what tangible outcomes resulted?
• Have you quantified the current gap to plan and do you have sensitivity models we can review during a diagnostic? Options: Yes — detailed model ready, Yes — high-level estimate only, No, but we can assemble quickly, Unknown

Who Really Holds the Keys?

• If execution stalls, where does it usually get stuck—sponsor approvals, CEO bandwidth, plant leadership, or something else? Options: Sponsor approvals / Investment Committee, CEO / Executive Team, CFO / Finance, Plant / Ops leadership, Board-level politics, Other
• Which stakeholders must be actively aligned for us to implement interim operating authority (name roles/titles)?
• Who in the group is likely to champion tough, fast operational trade-offs—and who has historically resisted them?
• Have any stakeholders blocked externally driven initiatives before? Tell us what happened and how long the resistance persisted.
• What proof-points or assurances would persuade the investment committee to give our team delegated decision rights during the diagnostic and early execution? Options: Pilot with limited scope, Success-fee alignment, Operating partner references / track record, Pre-agreed acceptance criteria, Other

Data: Is It Ready or Broken?

• If we asked to measure realized savings to the dollar, where will we hit the largest blind spots or manual workarounds? Options: Cost ledger mapping / Chart of Accounts, Customer-level pricing & discounts, Procurement PO history, WIP / manufacturing yield data, Receivables / working capital details, Other
• Can your team produce core datasets for a 100‑day diagnostic within 72 hours (ERP exports, GL, customer SKUs, PO history)? Options: Yes — ready within 72 hours, Partially — some extracts available, No — will take >1 week, Depends on scope / approvals
• Which systems are the authoritative sources (ERP, BI, specialized tools)? Please list system names and a primary contact for each.
• How often are operational systems reconciled to the GL today, and how long does reconciliation typically take? Options: Daily, Weekly, Monthly, Quarterly, Rarely / ad hoc
• Do you have a formal initiative-level savings attribution approach today, and if so, how are owners and measurement rules defined? Options: Yes — formal rules and owners, Yes — informal tracking, No — ad hoc or not tracked, Unsure
• Who on your team will act as primary data steward during the diagnostic and do they have dedicated bandwidth to support rapid extracts?

People, Roles, and Interim Authority

• Who will make the day‑to‑day operational decisions once our operators are embedded—and will they have the authority to act without repeated sponsor sign‑off?
• Which interim roles do you expect us to fill (select all that apply)? Options: Interim COO / GM, Interim Head of Procurement, Interim Head of Manufacturing / Plant Manager, Interim Head of Commercial / Pricing, Interim CFO / FP&A cover, No interim roles expected, Other
• For each interim role you select, is authority expected to be full operator-level, advisory only, or constrained (please list role:authority)?
• Are there contractual, labor, or cultural constraints we should anticipate when embedding external operators (unions, NDAs, customer site restrictions)? Options: Union constraints, Confidential customer contracts, Board approval required, IT/user access restrictions, No known constraints, Other
• What incentive levers can you deploy to ensure management actively supports rapid change (e.g., retention bonuses, short-term KPIs, equity), and who controls those levers?
• When decisions exceed pre-agreed authority, what escalation path do you prefer for day-zero operational calls? Options: Daily stand-up with CEO, Sponsor-level approval, Pre-authorized delegations for specific thresholds, Emergency governance call, Other

Money and Covenants: What's on the Line?

• Which covenant or lender covenant metric is closest to being breached if we need to temporarily fund an initiative? Options: Leverage / Net Debt to EBITDA, Interest coverage, Current ratio / liquidity, Debt service coverage, No covenant close to breach, Unknown
• What is the current approximate Net Debt / EBITDA band for the company? Options: <1.0x, 1.0–2.0x, 2.0–3.0x, 3.0–4.0x, >4.0x, Unknown
• Do existing finance documents allow for short-term working capital or capex drawdowns to pursue value-creation without a lender waiver? Options: Yes — permitted, Requires lender approval/waiver, No — not permitted, Unsure
• If an initiative requires incremental capital, what is the fastest realistic source (select one)? Options: Sponsor bridge funding, Reallocate existing working capital, Lender waiver / amendment, No feasible path within 90 days, Other
• What is the ballpark maximum incremental capital you could commit to initiatives in the next 90 days? Options: None, < $250k, $250k–$1M, $1M–$5M, > $5M, Unsure
• Who is the primary banking/debt contact and how quickly could they respond to a covenant or waiver request?

What Happens If We Don't Move?

• If no external intervention occurs, which single outcome would materially reduce exit value in the next 12 months? Options: Missed exit multiple / lower valuation, Covenant breach / restructuring risk, Loss of top customers, Continued margin erosion, Key management departures, Other
• Estimate the EBITDA at-risk over the next 12 months as a percentage or range. Options: <5% of plan, 5–10% of plan, 10–20% of plan, >20% of plan, Unknown
• Which customers, SKUs, or sites create the most tail risk to enterprise value, and why?
• How would LPs or the investment committee likely react to continued underperformance—replace management, accept lower exit, seek opportunistic sale, or escalate governance? Options: Replace management, Accept lower exit, Seek governance/board change, Explore strategic sale, Other
• Do you have existing contingency plans to preserve value (e.g., cost-shelter triggers, customer protection plans)? If yes, summarize.

Commitment & Governance: How We'll Stay Aligned

• If early performance lags against the 100‑day plan, what governance response would you expect—pause, pivot, double‑down, or personnel change? Options: Pause and reassess scope, Pivot resources / reprioritize initiatives, Double-down on execution, Immediate personnel change, Escalate to sponsor for decision
• Which governance cadence do you want during the first 100 days (choose all that should occur)? Options: Daily operational stand-ups, Weekly execution reviews, Bi-weekly sponsor steering, Monthly investment committee updates, Ad-hoc escalation calls
• Who must be on the core steering committee (list names/roles) and who should be optional observers?
• What success-fee alignment structure do you prefer for an engagement of this type? Options: Flat consulting fee, % of realized EBITDA (simple), Tiered % by speed/magnitude, Hybrid: retainer + % savings, Other
• What concrete acceptance criteria will the investment committee require to sign off that the diagnostic met its objectives?
• Which specific issues would be considered immediate red lines that require sponsor escalation? Options: Covenant breach, Customer loss >X% revenue, Material safety incident, Evidence of fraud, Operational shutdown of a major site, Other

Practical Access Roadmap

• What's the single most likely gatekeeper to delay our team's full operational access in week one? Options: IT / admin provisioning, Signed MSA / SOW, Data security approvals / NDA, Management resistance, Union / HR approvals, Other
• Which of these access items are already in place? (select all that apply) Options: Signed MSA / SOW, NDA in place, IT admin accounts provisioned, SFTP / API data feeds, Physical site access / badges, Data dictionary / schema, None of the above
• What date can you realistically grant full access to systems and facilities required for embedding? Options: Within 72 hours, Within 1 week, Within 2 weeks, Within 1 month, More than 1 month, Unsure
• Who is your primary IT/security contact for onboarding external operators and what approvals will they require?
• If access will be delayed, which mitigation would you prefer: focused remote work, phased on-site ramp, anonymized data modeling, or pause until resolved? Options: Remote-first for 30 days, Phased on-site ramp, Use anonymized / aggregated data, Pause until access granted, Other

A Quick Readiness Pulse

• How confident are you, right now, that leadership would publicly endorse scaling these initiatives tomorrow? Options: Very confident, Somewhat confident, Not confident, Unsure / need more input
• Which of the top initiatives already have explicit, documented acceptance from the CEO or board? Options: Pricing optimization, Procurement savings, Manufacturing productivity, SG&A rationalization, Working capital, None, Other
• Describe a recent instance where management gave a clear go-ahead for change—what did acceptance look and feel like?
• What are the three most common objections you hear from front-line leaders about implementing these initiatives?
• Who remains unconvinced and would need to be won over before large-scale embedding? Options: CEO, CFO, COO/Plant GM, Head of Sales, Head of Procurement, Board/IC rep, Lenders, Other

If We Scaled Today, What Would Break First?

• If we pushed to scale immediately, what single operational failure are you most worried would happen within 30 days? Options: Supply shortfalls, Order fulfillment delays, Data/reporting collapse, Cash/covenant breach, Loss of key customers, Employee turnover, Other
• Which operational constraints are most likely to derail rollout across sites or channels? Options: Data quality, IT integration, Skilled resource shortage, Supplier capacity, Physical capacity, Union/ labor limits, Regulatory permits, Other
• Tell us about a past scale attempt that stumbled—what caused the dominoes to start falling?
• How would you expect the earliest signs of failure to appear in KPIs (which metrics and what change magnitude)?
• Which sites, product lines, or customer segments are highest risk if the initiative is rolled out too fast? Options: Top 3 revenue sites, High-complexity SKUs, Strategic customer accounts, Newly integrated acquisitions, International operations, Other

Do Our Acceptance Criteria Actually Prove Value?

• For the prioritized initiatives, how many have SMART acceptance criteria (specific, measurable, owner, timeframe)? Options: All prioritized initiatives, Most (60–80%), Some (30–60%), Few or none
• Please list acceptance criteria for your top three initiatives—include the metric, the target, the owner, and the date by which it must be met.
• When savings overlap (for example pricing and channel mix), how will attribution be decided? Options: Owner-assigned rules, Pre-agreed allocation model, Independent validation/audit, Sponsor judgement, Not yet decided
• What measurement tolerance (e.g., ±% or $) will be treated as acceptable before disputes are escalated? Options: ±0.5%, ±1%, ±2%, ±5%, Set per-initiative
• Who has final sign-off authority on whether an initiative has met its acceptance criteria? Options: Portfolio Operating Partner, CEO, CFO, Investment Committee representative, Independent auditor, Other

Who’s Holding the Measuring Tape?

• Who will be accountable for day-to-day measurement and maintaining data integrity for realized savings? Options: Internal finance / FP&A, Business unit controller, Dedicated program manager, Third-party validator, Sponsor analytics team, Not yet assigned
• Describe the reporting cadence and the minimum data flow (reports, dashboards, raw extracts) required to validate progress.
• Will an internal audit or an external third party perform periodic validation of savings? Options: Internal audit, External third-party, Both, No validation planned
• What specific tools, models, or templates will be used to ensure repeatable, auditable measurement? Options: Standard P&L reconciliation, Attribution model template, Time-series KPI dashboard, ERP/extract protocols, Other
• If data gaps exist today, how long to resolve them and who is responsible?

Covenants, Compliance and Capital — Are We Riding a Time Bomb?

• Which debt covenants or regulatory constraints are most likely to be impacted by the projected initiative outcomes? Options: Leverage ratio, Interest coverage, Minimum liquidity, Asset sale restrictions, Tax/transfer pricing rules, Industry-specific regs, None / unsure
• Have you stress-tested covenant headroom across downside scenarios that include implementation disruption? Options: Yes—full modelling, Partial modelling, Not yet modelled, Not applicable
• If an initiative needs capital expenditure, what approval steps and timing are required to secure funding without breaching covenants?
• Are there compliance or audit activities that must be run in parallel to the initiative to avoid regulatory exposure? Options: Yes—compliance team mandatory, Yes—external counsel required, No special activities, Unsure
• Who will be the single point of contact for lender communications if covenant questions arise? Options: CFO, CEO, Sponsor rep, External counsel, Other

Decision Gates: What Are the Hard Stop/Go Criteria?

• What are the non-negotiable pass/fail criteria at the first 30/60/90-day gates before we scale?
• Who is empowered to call a pause or green-light at each gate, and what documentation do they require? Options: CEO, CFO, Sponsor OP, Investment Committee delegate, Joint sign-off
• What minimum evidence package (metrics, audits, stakeholder attestations) will be accepted to clear a gate?
• How fast can we operationally pause or reverse a change if the gate criteria fail? Options: Immediate (<48 hours), 3–7 days, 2–4 weeks, Longer than 4 weeks
• What escalation path exists if a gate decision is contested? Options: Sponsor escalation to IC, Independent review, Executive committee decision, Mediation with lenders, Other

People, Roles and Embedded Operating Rhythm

• Are named initiative owners empowered with the decision rights and time allocation needed to deliver outcomes? Options: Fully empowered, Partially empowered, Not empowered, Not assigned
• Please name the owner for each priority initiative and list their top two constraints (capacity, budget, authority, skills, other).
• Which interim operating roles (acting CFO, interim plant manager, dedicated program lead) must be in place before scaling? Options: Interim CFO, Program manager, Embedded operations lead, Interim commercial leader, None required, Other
• How will you monitor change fatigue and frontline morale as initiatives are embedded? Options: Pulse surveys, People metrics (turnover/absenteeism), Manager check-ins, HR escalation triggers, Other
• What is the agreed cadence for governance reviews during scale (weekly, biweekly, monthly) and who must attend? Options: Weekly, Biweekly, Monthly, Ad-hoc

Proof, Attribution and Exit Reporting

• What will the exit reporting package include to prove sustainable EBITDA uplift (minimum deliverables)? Options: Reconciled P&L bridge, KPI trend lines, Savings attribution workbook, Operational SOPs/handover, Audit log of assumptions, Other
• Which portions of identified savings do you classify today as recurring versus one-time, and why? Options: Recurring, One-time, Mixed/depends, Undecided
• How will you demonstrate that realized savings are durable after the program team exits?
• What threshold of realized EBITDA uplift will be considered material for exit valuation and who sets that threshold? Options: >1 point, >2 points, >3 points, Set by IC, Other
• Who will own the post-exit monitoring plan to ensure savings stick for 6–12 months? Options: Internal operations, CFO/finance, Sponsor monitoring team, Third-party assurance, No plan yet

A Small Fail-safe Plan — If This Falters

• If an initiative misses targets by more than 20% at the 90-day checkpoint, what immediate actions should be triggered? Options: Pause scaling, Conduct root-cause analysis, Reassign resources, Increase governance frequency, Renegotiate targets, Other
• Who will lead the rapid root-cause investigation and what is an acceptable turnaround time for recommendations? Options: Internal ops lead, Sponsor operations, Third-party specialist, Joint team
• What short-term financial contingency (working capital or reserve) exists to absorb implementation shocks? Options: Dedicated reserve, Reallocated cash, Bank facility, No contingency, Undecided
• How should setbacks be communicated to the Investment Committee and lenders to preserve credibility?
• What criteria would cause you to permanently halt an initiative rather than rework it? Options: Sustained negative customer impact, Severe covenant threat, Net-negative cash impact, Regulatory violation, Other

Next Steps: Clear Commitments Before We Flip the Switch

• Before we begin scaling, what three named commitments (person + action + firm date) must be confirmed?
• Which formal documents need sign-off (commercial terms, governance calendar, success-fee amendment, data access agreements, others)? Options: Commercial terms, Governance calendar, Success-fee amendment, Data access agreement, SLA for interim roles, Other
• What is the earliest acceptable window to initiate scaling once these commitments are in place? Options: Immediately, Within 2 weeks, Within 30 days, 30–60 days, Later than 60 days
• If you had to state one non-negotiable condition that would stop you from scaling, what would it be?
• Who will send the formal go/no-go notice and what channel will be used (email, portal, signed memo)? Options: Sponsor OP via portal, CEO via signed memo, CFO via email, IC delegate via formal notice, Other